Health Technology/clinical-trials

Adaptive Trial Evaluates mHealth vs Conventional Support for MDR-TB/HIV Co-infection — Novel Bedaquiline Regimen Adherence Study

247 Health News Editorial

·

14 June 2026

·

3 min read

·clinical-trials

New adaptive trial in South Africa evaluates mHealth and psychosocial support interventions for patients with MDR-TB/HIV co-infection starting bedaquiline-containing regimens. Results could transform adherence monitoring in resource-limited settings.

Originally reported by ClinicalTrials.gov

References

  1. 1.Alipanah, N., Jarlsberg, L., Miller, C., Linh, N. N., Falzon, D., Jaramillo, E., & Nahid, P. (2023). Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies. PLoS Medicine, 20(1), e1003799. https://doi.org/10.1371/journal.pmed.1003799
  2. 2.Columbia University. (2024). Adaptive Evaluation of mHealth and Conventional Adherence Support Interventions to Optimize Outcome With New Treatment Regimens for Drug-resistant Tuberculosis and HIV in South Africa. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT05633056
  3. 3.Dheda, K., Mirzayev, F., Cirillo, D. M., Udwadia, Z., Dooley, K. E., Chang, K. C., ... & Furin, J. (2024). The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. The Lancet Respiratory Medicine, 12(4), 285-312. https://doi.org/10.1016/S2213-2600(24)00043-6
  4. 4.Nachega, J. B., Adeoti, O. M., Knowlton, A. W., Efron, A., Tlali, M., Moshabela, M., ... & Gandhi, M. (2023). Digital health interventions to improve HIV and tuberculosis treatment adherence and outcomes in sub-Saharan Africa. The Lancet Digital Health, 5(8), e528-e540. https://doi.org/10.1016/S2589-7500(23)00089-1
  5. 5.Ndjeka, N., Schnippel, K., Master, I., Meintjes, G., Maartens, G., Romero, R., ... & Hughes, J. (2023). Treatment outcomes among patients with multidrug-resistant tuberculosis in South Africa. International Journal of Tuberculosis and Lung Disease, 27(8), 594-601. https://doi.org/10.5588/ijtld.22.0456
  6. 6.Pontali, E., Sotgiu, G., Tiberi, S., Tadolini, M., Visca, D., D'Ambrosio, L., ... & Migliori, G. B. (2023). Bedaquiline and drug-resistant tuberculosis: a comprehensive review of pharmacokinetics, safety, and resistance. European Respiratory Journal, 61(3), 2200463. https://doi.org/10.1183/13993003.00463-2023
  7. 7.WHO Global Tuberculosis Programme. (2023). Global tuberculosis report 2023. World Health Organization. https://www.who.int/publications/i/item/9789240083851
Share:XLinkedIn
2

247 Health News Editorial

247 Health News is a medical intelligence platform delivering evidence-based research appraisals, clinical trial monitoring, and health technology news for healthcare professionals.

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service